Chronic pain patients are frequently maintained on one or more powerful opioid medications in combination with other psychoactive medications. Urine tests provide objective information regarding patient compliance status. Little information is available on testing this unique population. The goal of this study was to characterize drug disposition patterns in urine specimens collected from a large population of pain patients. Confirmation data for 10,922 positive specimens were collated into 11 drug Classes. The number of drug/metabolites tested (#) and number of confirmed positive specimens were as follows: amphetamines (7), 160; barbiturates (5), 308; benzodiazepines (6), 2397; cannabinoids (1), 967; carisoprodol (2), 611; cocaine (1), 310; fentanyl (1), 458; meperidine (2), 58; methadone (2), 1209; opiates (7), 8996; and propoxyphene (2), 385. Subdivision into 19 distinct drug Groups allowed characterization of drug use patterns. Of the 10,922 positive specimens, 15,859 results were reported as positive in various drug Classes, and 27,197 drug/metabolites were measured by gas chromatography-mass spectrometry. The frequency of illicit drug use (cannabis, cocaine, ecstasy) was 10.8%. Being the first study of this type, these data present a large array of information on licit and illicit drug use, drug detection frequencies, drug/metabolite patterns, and multi-drug use combinations in pain patients.
Introduction
Chronic pain is broadly prevalent, ranging from 2% to 40% in the general adult population (1), but pain sufferers often find it difficult to obtain effective medications and long-term relief. Clinicians offering treatment for chronic pain are faced with multiple divergent problems in their practice. Both undertreatment and over-prescribing bring risks not only to patients but also possible legal sanctions to the health care specialists offering treatment. Opioid medications are the cornerstone of pain management; some 90% of chronic pain patients are currently being prescribed these drugs (1). Although the use of opioids is widely accepted in treatment of cancer pain, their use in treatment of chronic nonmalignant pain remains controversial, primarily because of the lack of safety and efficacy data for this treatment approach (2) . It is understood that long-term use of opioids in chronic pain patients brings about the development of tolerance and physical dependence (3) , and these medications have powerful reinforcing properties and high abuse potential. Of concern is the possibility that patients will develop maladaptive behavioral changes and become addicted. Behaviors associated with drug addiction have been characterized as loss of control over use, continued use despite knowledge of harmful consequences, compulsion to use, and craving (4, 5) .
Diagnosis of drug addiction in chronic pain patients has been reported to range from 3.2 to 23.4% (6, 7) , and drug overuse and abuse prevalence may be as high as 41% (1). Behaviors suggestive of opioid addiction include selling prescriptions; prescription forgery; concurrent use of illicit drugs; recurrent loss of prescription; unsanctioned dose escalations; stealing or borrowing drugs from others; and "doctor shopping" (4). Gourlay et al. (8) advocated a "universal precautions" approach for health care professions offering treatment of chronic pain. This model offers a minimum level of care applicable to all patients presenting with chronic pain and calls for a treatment agreement between patient and practitioner that sets behavioral boundaries. Urine drug testing is recommended as a component of treatment agreements to assist in therapeutic decisions. Those patients found to be using illicit or unauthorized drugs should be referred for assessment of possible addictive disorders.
The value of urine drug testing in chronic pain management lies in its ability to identify recent use of prescribed and unauthorized drugs and illicit drugs. For example, one retro-spective study of 470 chronic pain patients revealed that 45% had abnormal urine results (absence of prescribed opioid, presence of illegal drugs, or presence of nonprescribed opioids) (9) . Despite its obvious value to clinicians involved in monitoring patient adherence to chronic opioid therapy, urine drug testing in this population appears to be greatly under-utilized. A report in 2001 (10) indicated that 42% of primary care physicians engaged in treatment of chronic pain utilized written drug agreements, but only 8% used urine toxicology screening. A more recent report in 2006 (11) found that 6.9% of primary care physicians utilized urine toxicology tests for patients before prescribing opioids and only 15% for patients already prescribed opioids. The reasons for under-utilization of urine toxicology tests in chronic pain management practices are unclear, but most likely include factors such as physicians' lack of experience and knowledge of drug tests, lack of standardization of test methods, and financial considerations and resource requirements. Furthermore, there appears to be little published in toxicology literature concerning testing of chronic pain patients on a large scale.
The lack of toxicological information on drug testing of chronic pain patients led us to evaluate a database of 10,922 confirmed urine results from 31 pain clinics in 6 states. The database contained quantitative information on 32 drug/metabolites originating from 11 drug classes. The goals of the study were to characterize the prevalence, patterns, and concentrations of therapeutic drugs and metabolites in this population and to determine the prevalence of cannabis, cocaine, and ecstasy-type drug use.
Materials and Methods

Reagents and supplies
All drug reference standards and deuterium-labeled internal standards were purchased from Cerillant (Round Rock, TX). Tetrabutylammonium hydrogen sulfate (TBAHS) and β-glucuronidase (LII, from limpets Patella vulgate) were purchased from Sigma (St. Louis, MO). N-Methyl-N-(tert-butyldimethylsilyltrifluroacetamide (MTBSTFA), heptafluorobutyric anhydride (HFBA), N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA), and N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) were purchased from Campbell Science (Rockton, IL). Iodotrimethylsilane (ITMS) was purchased from Fisher Scientific (Pittsburgh, PA). Iodomethane was purchased from Sigma-Aldrich (St. Louis, MO). All solvents and reagents were reagent grade quality. Solid-phase extraction columns were the GV65 column (Biochemical Diagnostics, Edgewood, NY) and ZSDAU020 column (United Chemical Technologies Worldwide Monitoring, Bristol, PA).
Specimens
A total of 13,948 urine specimens were collected over the period of January through December 2006 from 31 pain clinics located in 6 states (TN, WV, KY, OH, FL, IN). The specimens were screened and confirmed by Aegis Sciences (Nashville, TN) for a range of prescribed and illicit drugs. A total of 10,922 specimens screened positive and were confirmed positive for at least one drug and/or metabolite. The confirmed positive results were assembled into a "Pain Patient" database containing only test results. No patient information was included. All specimen data were coded to protect patient confidentiality. No medication history was available for interpretation of results.
Screening procedures
Screening was performed with CEDIA reagents (Microgenics) on Hitachi 717 (Boehringer Mannheim/Hitachi, Indianapolis, IN) automated analyzers or with ELISA reagent kits (Immunalysis) processed on an EVO 150 liquid handling system (TECAN, Research Triangle Park, NC). Urine specimens were initially screened for amphetamines, barbiturates, benzodiazepines, cannabinoids, carisoprodol, cocaine, ecstasy, fentanyl, meperidine, methadone, opiates, oxycodone, and propoxyphene by immunoassay following manufacturer's procedures. Table I lists manufacturer, cutoff concentrations, analytes, and cross-reactivity data for each screening assay.
Confirmation procedures
All specimens that screened positive were analyzed by gas chromatography-mass spectrometry (GC-MS). The GC-MS systems used for all confirmatory analyses were Agilent 5973 and 5975 GC-MS instruments (Agilent Technologies, Wilmington, DE). The analytes tested in each drug Class were as follows: amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxyethylamphetamine (MDEA), 3,4-methylenedioxymethamphetamine (MDMA), p-methoxyamphetamine, and phentermine (Amphetamines); amobarbital, butabarbital, butalbital, pentobarbital, and secobarbital (Barbiturates); α-hydroxyalprazolam, clonazepam, lorazepam, nordiazepam, oxazepam, and temazepam (Benzodiazepines); 11-nor-9-carboxy-∆ 9 -tetrahydrocannabinol (THCCOOH) (Cannabinoids); carisoprodol and meprobamate (Carisoprodol); benzoylecgonine (Cocaine); fentanyl (Fentanyl); meperidine and normeperidine (Meperidine); 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and methadone (Methadone); codeine, dihydrocodeine, hydrocodone, hydromorphone, morphine, oxycodone, and oxymorphone (Opiates); and norpropoxyphene and propoxyphene (Propoxyphene). Specimens screening positive in either the Amphetamines or the Ecstasy immunoassay were confirmed in the Amphetamines Group assay. Specimens that screened positive in either the Opiates or the Oxycodone immunoassay were confirmed in the Opiates Group assay.
GC-MS separations were achieved with either a DB-1 column (TMS derivatives) or DB-5MS column (J&W Scientific, Folsom, CA). The column dimensions were 20 m × 0.25 mm with a 0.25-µm film thickness. All chromatographic separations were performed with optimized temperature programs for each drug group. MS data acquisition utilized selected ion monitoring for each analyte and appropriate deuterated internal standards. Quantitation was based upon a single-point calibrator included with each analytical run and included open positive and negative control samples prepared in a urine matrix. All confirmation assays were validated for sensitivity, selectivity, linearity, accuracy, and precision. Table II provides a summary of extraction procedures for each drug Group and associated validation information. Specimens with drug concentrations exceeding the upper limit of linearity (ULOL) of the assay were reanalyzed following serial dilution with solvent until concentrations were below the ULOL.
Database analysis
The confirmed results for the 10,922 urine specimens were assembled in a "Pain Patient Database" for assessment of drug/metabolite prevalence rates, patterns, and concentrations. Drug/metabolite concentrations were recorded in the database if analyte concentrations ≥ the limit of quantitation (LOQ) of the confirmation assay. Initially, the database was divided into 11 drug Classes for assessment of within-Class prevalence and patterns. The drugs/metabolites quantitated in each drug Class were identical to those listed in Confirmation Procedures. No confirmed positive results were recorded for the following drugs: p-methoxyamphetamine, MDEA, amobarbital, and pentobarbital.
A further subdivision of the database into distinct drug Groups was made. Positive results were categorized into drug Groups that contained parent (commercial) drug(s) and known metabolites. The rationale for these groupings was their usefulness in interpreting the number of distinctly different drugs used by each patient. A limitation of this approach to interpretation was the complex metabolic patterns of some drug Groups (e.g., benzodiazepines). For example, it is known that diazepam administration can produce positive results for diazepam, nordiazepam, temazepam, and oxazepam, all of which are commercial products. Because of the difficulty in determining which benzodiazepine(s) was administered, positive results for all combinations of these analytes were combined into the "Diazepam Group". This conservative approach will in some cases underestimate the number of drugs consumed by patients, for example, a positive test for temazepam and oxazepam could arise from use of a single drug, diazepam or temazepam, or from combinations of diazepam, temazepam, and oxazepam.
Nineteen distinctive drug Groups were created as follows: Amphetamines Group, 
Results and Discussion
Technology considerations in drug testing of chronic pain patients Analytical procedures employed in clinical testing of chronic pain patients have different requirements than those found generally in conventional workplace and legal settings. Whereas workplace and legal testing programs tend to focus primarily on detection of illicit drug use, there are broader considerations in testing pain patients. Health treatment specialists are interested in determining if patients are using medications appropriately, if unauthorized drugs are being used, and if there are signs of existing or developing addiction. Chronic pain patients are frequently stabilized on high daily doses of a controlled-release (or long-acting) opioid formulation, but many experience transitory flares of pain beyond moderate intensity requiring treatment with an immediate-release opioid formulation (1). In addition, comorbidity is common in this population (12) requiring treatment with numerous other psychoactive drugs, many of which have significant abuse liability properties. Consequently, the number of assays required in pain testing is considerably greater than in other settings. In the current study, 13 commercial immunoassays and 11 GC-MS assays (capable of measuring 36 drug/metabolites) were utilized in the testing of patient specimens.
Laboratory-based test procedures for pain patients typically follow the standard workplace-type test sequence (i.e., screening by immunoassay followed by confirmation testing of presumptive positive specimens with GC-MS). However, unlike workplace testing, the confirmation rate for testing pain patients is extremely high. In the current study, approximately 78% of all patient specimens (10,922 of 13,949) required GC-MS confirmation for at least one drug/metabolite. Of specimens with confirmed results, (N = 10,922), single drug use accounted for 62.3% of all positives. Multiple drug use was evident in the remainder of the specimens. The frequency of multiple drug use was as follows: two drugs, 26.4%; three drugs, 8.2%; four drugs, 2.4%; five drugs, 0.5%; six drugs, 0.2%; and seven drugs, 0.02%. Similar findings of polymedication in chronic non-malignant pain patients was reported by Berndt et al. (13) . Given these considerations, extremely high confirmation rates are to be expected in pain management testing as part of normal laboratory operations. Analytical performance requirements for pain testing also differ from the workplace and legal settings. Screening and confirmation procedures must have sufficient sensitivity to detect occasional drug use at low concentrations (e.g., medications prescribed for use "as needed"). At the same time, these assays must be sufficiently flexible to measure drug/metabolite concentrations across wide ranges up to ultra-high concentrations. To avoid exceeding assay ULOL in the current study, immunoassay responses were used as guides for dilution prior to GC-MS confirmation. Overall, resource and technology requirements for production of data in this study were immense. Almost 14,000 specimens from chronic pain patients were screened by 13 different immunoassays during 2006 (> 180,000 immunoassay tests). A total of 10,922 specimens were confirmed positive by GC-MS for at least one drug/metabolite. Of the 10,922 positive specimens, 15,859 results were reported as positive in various drug Classes (Table III) . Thus, approximately 45% of all confirmed specimens were positive for more than one drug Class and required two or more GC-MS confirmation assays for completion of the analysis. Multiple drug/metabolites were identified in many drug Classes leading to a reporting total of 27,197 analytes for the 10,922 specimens.
Drug/metabolite patterns in urine specimens from pain patients
Of the 13,948 urine specimens collected from pain patients in 2006, a total of 10,922 specimens were confirmed positive by GC-MS for one or more drug analytes. These data were collated in a "Pain Patient Database" and sub-divided into 11 drug Classes for assessment of patterns and prevalence of drugs and metabolites in this population. An overview of results is presented in Table III . The frequency of confirmed positives (at least one positive within the drug Class) was as follows (decreasing order): Opiates (82.4%); Benzodiazepines (21.9%); Methadone (11.1%); Cannabinoids (8.9%); Carisoprodol (5.6%); Fentanyl (4.2%); Propoxyphene (3.5%); Barbiturates (2.8%); Cocaine (2.8%); Amphetamines (1.5%); and Meperidine (0.5%). As expected, the overall positivity rate was highest for the opiates Class with benzodiazepines following at a distant second. In pain management settings, it has been reported that as many as 90% of patients receive opioids for treatment (1). This is consistent with findings in the present study in which 92.5% of all positive specimens contained at least one of the five opioids in the test panel (fentanyl, meperidine, methadone, opiates, and propoxyphene). A high rate of benzodiazepine use and abuse also has been reported by chronic pain patients. The rate of benzodiazepine use prior to presenting to a pain management clinic has been reported to as high as 42% (1).
Table IV provides a detailed listing within each drug Class of drug/metabolite prevalence, percent positivity, and concentration data for 32 drug/metabolites. Of the 36 analytes that could be measured, four drugs (MDEA, p-methoxyamphetamine, amobarbital, and pentobarbital) were not detected in any specimen. Table V contains a complete tabulation of drug/metabolite patterns and positivity rate within each drug Class. 
Amphetamines
A total of 160 (1.5%) urine specimens were positive for one or more drugs/metabolites in the amphetamines Class. The frequency of amphetamines reported positive was as follows (decreasing order): amphetamine (75.6%); methamphetamine (25.6%); phentermine (21.9%); MDA (2.5%) and MDMA (1.9%). Mean concentrations (Table IV) 
Within Class pattern analysis of the amphetamines analytes is shown in Table V . Amphetamine was the most frequently reported result (51.3%). Of the 41 specimens that were positive for methamphetamine, 39 were found in combination with amphetamine. The median amphetamine/methamphetamine ratio for the 39 specimens (range) was 85.6% (4.5-2761.3%). Oyler et al. (14) reported that this ratio varied from 1% early after dosing to 260% late in the excretion phase following controlled dosing of methamphetamine to human subjects. In the current study, 25 of the specimens positive for both methamphetamine and amphetamine had amphetamine/methamphetamine ratios within the range observed in the Oyler study, and 14 specimens positive had ratios > 260%. A possible explanation for those specimens with ratios > 260% is concurrent use of both methamphetamine and amphetamine.
Phentermine was reported as the sole analyte in 33 specimens (20.6%) of the amphetamines Class; two specimens contained a combination of phentermine, methamphetamine and amphetamine (Table V) .
MDA was positive in four specimens, three of which also contained MDMA. The %MDA/MDMA ratio for the three specimens ranged from 10.4% to 36.9%. Fallon et al. (15) reported somewhat similar ratios following administration of 40 mg of MDMA to healthy volunteers. During the first 24 h of collection, %MDA/MDMA ratios ranged from 5.9% to 17%. For the four positive specimens in this study, it is probable that MDMA use occurred in three instances. MDA use most likely accounts for the MDAonly positive specimen. Interestingly, use of other illicit drugs was apparent for these specimens as well. All four specimens were also positive for THCCOOH, and one specimen was positive for benzoylecgonine.
Barbiturates
A total of 308 (2.8%) urine specimens were positive for one or more barbiturates in the barbiturates Class. The frequency of barbiturates reported positive was as follows (decreasing order): butalbital (98.7%); secobar- bital (1.6%); and butabarbital (0.3%). Mean concentrations (Table IV) were highest for secobarbital followed in decreasing order by butalbital and butabarbital. Within Class pattern analysis of the barbiturates is shown in Table V . Butalbital was the predominant reported result (98.1%). Two specimens were found to be positive for two different barbiturates.
Between drug Group analysis revealed that butalbital appeared twice among the 25 most frequently reported single/multiple drug Group combinations (Table VI, #16 , combination with hydro-opiate drugs and #19, single drug). A possible explanation for the high prevalence of butalbital is its continued popular use in various combinations with caffeine, aspirin, acetaminophen, and codeine for the treatment of tension-type and migraine headache (16) . Assessment of the 89 specimens in which butalbital was found in combination with Hydro-Opiates revealed that 14 patients had used butalbital in combination with codeine, thus lending some credence to the possible use of butalbital for headache treatment. One further aspect concerning the use of butalbital for headache treatment is its possible relationship to abuse of other substances. A report by Elkind (17) suggested that substance abuse occurs frequently in chronic headache sufferers. Accordingly, evidence for illicit drug use was examined in the 304 patients found positive for butalbital. Of these, 17 patients were positive for THCCOOH (5.6%), and an additional 5 were positive for benzoylecgonine (1.6%) for an overall total of 7.2%. This frequency of illicit drug use by butalbital users was no higher than the overall rate of illicit drug use (see Evidence of illicit drug use in pain patients section) observed in this study for the entire group of pain sufferers.
Benzodiazepines
A total of 2397 (21.9%) urine specimens were positive for one or more drugs/metabolites in the benzodiazepines Class. The frequency of benzodiazepines reported positive (Table IV) zolam were frequently reported in various combinations and occasionally with lorazepam. Interpretation of which or how many benzodiazepines were used by a patient can be difficult because of the complex metabolic patterns of some of these drugs (18) . For example, diazepam can be metabolized to nordiazepam, temazepam, and oxazepam, all of which are also available as commercial products. Temazepam can be metabolized to oxazepam, and chlordiazepoxide can be converted to nordiazepam and oxazepam. In contrast to these structurally similar benzodiazepines, α-hydroxyalprazolam (metabolite of alprazolam), clonazepam, and lorazepam have unique molecular structures that allow definitive interpretation of which drug was administered. By grouping the "diazepam-related" drugs together as one group, "diazepam", an assessment was made of how many different benzodiazepines were used by patients with positive benzodiazepine results (N = 2397). With this approach, it was determined that use of a single benzodiazepine (alprazolam, clonazepam, "diazepam", or lorazepam) accounted for 90.0% of the benzodiazepine patterns. Use of two and three different benzodiazepines was indicated in 9.5% and 0.5% of the patterns, respectively. However, it should be noted that this assessment is limited by the possibility that co-administration of two or more of the commercial "diazepam-related" benzodiazepines was possible and quite likely in some cases.
For an assessment of which benzodiazepine were used, specimens with results consistent with use of a single benzodiazepine were evaluated (N = 2157; 90% of all benzodiazepine positive specimens). The frequency of benzodiazepines use was as follows (decreasing order): "diazepam" (65.3%), alprazolam (27.5%), clonazepam (5.7%), and lorazepam (1.4%).
Between-drug Group analysis revealed that benzodiazepine analytes appeared 9 times among the 25 most frequently reported single/multiple drug Group combinations (Table VI) . Seven of the most frequent drug group combinations were associated with diazepam, alprazolam, or clonazepam in combination with an opioid, and two were single drug use (#10, diazepam and #24, alprazolam). Although the use of benzodiazepines for patients with chronic pain is controversial, they are commonly prescribed for sleep improvement (19) and as adjuncts to opioid therapy (20) . Thus, the overall high frequency of benzodiazepine use observed in this study (N = 2397; 21.9%) appears to be consistent with current prescribing practices for chronic pain patients (19) .
Cannabinoids
A total of 967 (8.9%) urine specimens were positive for THC-COOH (Cannabinoids). Mean, median, and range of concentrations for THCCOOH (Table IV) were 177, 40, and 2-11,554 ng/mL, respectively.
Between-drug Group analysis revealed that THCCOOH appeared 3 times among the 25 most frequently reported single/multiple drug Group combinations (Table VI) . Specimens positive only for THCCOOH were ranked #8 in frequency. THC-COOH in combination with hydro-opiates was ranked #7 and in combination with oxy-opiates was #25. Other studies in small populations of chronic pain patients on opioid therapy have reported cannabis use to range from 6.2% to 16.4% (9,21-23 ).
The high prevalence of cannabis use in this population could possibly be due to patient attempts at self-medication. Over the last decade, the benefits of cannabis treatment for pain and sleep disorders have been reported (24) . Importantly, cannabinoids have been shown to produce analgesia via endocannabinoids that work in tandem with endogenous opioids (25) , thereby offering new therapeutic options in the treatment of chronic pain (26) . One prospective study of Canadian patients (N = 209) suffering from chronic non-cancer pain found that 15% reported having previously used cannabis for pain relief, and 10% were current cannabis users for pain relief (27) .
Carisoprodol
A total of 611 (5.6%) urine specimens were positive for carisoprodol and/or meprobamate in the carisoprodol Class. Meprobamate was reported in highest frequency at 94.1% and carisoprodol was reported at 44.8%. Mean concentrations (Table IV) were highest for meprobamate followed by carisoprodol.
Within Class pattern analysis of the carisoprodol analytes indicated that meprobamate, and meprobamate in combination with carisoprodol, accounted for 55.0% and 39.1% of the results, respectively (Table V) . Carisoprodol, in the absence of meprobamate, was identified in 5.9% of the specimens. Carisoprodol is a powerful muscle relaxant and is used most often to treat acute pain due to muskoskeletal injury. Consequently, the prevalence of this drug in this population was not surprising.
Because meprobamate is a major metabolite of carisoprodol, and both compounds are prescription products, it was not always possible to determine which drug was administered. Both drugs are known to be abused (28), but carisoprodol is not a federally scheduled compound, whereas meprobamate is a Schedule IV drug. Consequently, carisoprodol is likely to be more widely prescribed than meprobamate. In the same vein, carisoprodol use most likely accounts for most of the positive results recorded in this study for this drug Class.
Between-drug Group analysis revealed that carisoprodol/ meprobamate in combination with hydro-opiates ranked #11 in the 25 most frequently reported drug combinations.
Cocaine
A total of 310 (2.8%) urine specimens were positive for benzoylecgonine, a metabolite of cocaine. Mean, median, and range of concentrations (Table IV) were 18,322, 1043, and 50-425,055 ng/mL, respectively. Other studies in small populations of chronic pain patients on opioid therapy have reported cocaine use to range from 2.2% to 6.8% (9, (21) (22) (23) . A total of 81 (26.1%) specimens that were positive for benzoylecgonine were also positive for THCCOOH.
Fentanyl
A total of 458 (4.2%) urine specimens were positive for fentanyl. Mean, median, and range of concentrations (Table IV) were 87, 23, and 1-2382 ng/mL, respectively.
Between-drug Group analysis revealed that fentanyl appeared 2 times among the 25 most frequently reported single/multiple drug Group combinations (Table VI) . Specimens positive only for fentanyl were ranked #14 in frequency. Fentanyl in combination with hydro-opiates was ranked #15.
Meperidine
A total of 58 (0.5%) urine specimens were positive for meperidine and/or normeperidine in the meperidine Class. Normeperidine was reported in slightly higher frequency at 69.0% than meperidine at 62.1%. Mean concentrations (Table  IV) were slightly higher for meperidine compared to normeperidine.
Within-Class pattern analysis of the meperidine analytes indicated that normeperidine and meperidine separately accounted for 37.9% and 31.0% of the results, respectively (Table  V) . Meperidine, in combination with normeperidine, was identified in 31.0% of the specimens.
Methadone
A total of 1209 (11.1%) urine specimens were positive for methadone and/or EDDP in the methadone Class. EDDP was reported in slightly higher frequency at 93.8% than methadone at 87.3%. Mean concentrations (Table IV) were higher for the metabolite compared to methadone.
Within-Class pattern analysis of the methadone analytes indicated that methadone in combination with EDDP accounted for 81.1% of the results (Table V) . EDDP and methadone were identified separately in 12.7% and 6.2% of the specimens, respectively.
Between-drug Group analysis revealed that methadone analytes appeared four times among the 25 most frequently reported single/multiple drug Group combinations (Table VI) . Specimens positive only for methadone analytes were ranked #4 in frequency. Methadone analytes also were found with other drug Classes in the following combinations: hydro-opiates, #12; oxy-opiates, #17; and diazepam, #22.
Opiates
A total of 8996 (82.4%) urine specimens were positive for opiate analytes in the opiates Class. The frequency of opiates reported positive (Table IV) was as follows (decreasing order): hydrocodone (63.9%); hydromorphone (41.1%); dihydrocodeine (25.3%); oxycodone (23.0%); oxymorphone (18.1%); morphine (11.8%); and codeine (1.5%). Mean concentrations were highest for morphine followed in decreasing order by codeine, oxycodone, oxymorphone, hydrocodone, hydromorphone, and dihydrocodeine.
Within-Class pattern analysis of the opiate analytes presented a complex array of drug/metabolite combinations. A total of 73 different opiate analyte combinations were reported for this group of pain patients. Table V lists all opiate combinations occurring at a prevalence rate of ≥ 10. Hydrocodone was the most frequently reported single analyte (23.2%) followed by hydromorphone (6.1%), oxycodone (4.8%), morphine (4.4%), oxymorphone (0.7%), dihydrocodeine (0.6%), and codeine (0.3%). Hydrocodone was most frequently reported in various combinations with other opiates.
Interpretation of which or how many opiates were used by a patient can be difficult because of the complex metabolic patterns of some of these drugs. For example, codeine can be metabolized to morphine and in minor amounts to hydrocodone (29) ; morphine can be metabolized in minor amounts to hydromorphone (30) ; hydrocodone can be metabolized to hydromorphone and dihydrocodeine (31) ; and oxycodone can be metabolized to oxymorphone (32) . All of these opiates also are available as commercial analgesic products. The major chemical structural difference in these drugs is the presence of a hydroxyl-group at the C-14 carbon atom site of oxycodone and oxymorphone and its absence in the other opiate-type drugs. By dividing these two distinct types of drugs into two separate drug Groups designated as "Hydro-Opiates" (codeine, dihydrocodeine, morphine, hydrocodone, and hydromorphone) and "Oxy-Opiates" (oxycodone and oxymorphone), an assessment was made of how many single uses and combinations of these two distinct types of opiates occurred in this population. With this approach, it was determined that use of a single hydro-opiate accounted for 75.4% of the observed opiate patterns. Use of a single oxy-opiate accounted for 17.9% and combined use of both types of drugs occurred in 6.8% of the observed patterns. However, as occurred in the benzodiazepine assessment, this evaluation is limited by the possibility that coadministration of two or more of the drugs within each group was possible and quite likely in some cases. (Table VI) . Specimens positive only for hydro-opiates were ranked #1 in frequency. Hydro-opiate analytes also were found with other drug Classes in the following combinations: diazepam, #3; oxy-opiates, #5; α-HO-alprazolam, #6; cannabinoids, #7; carisoprodol-meprobamate, #11; methadone, #12; fentanyl, #15; butalbital, #16; propoxyphene, #18; diazepam/oxy-opiates, #20; and clonazepam, #23. Specimens positive only for oxy-opiates were ranked #2 in frequency. Oxy-opiate analytes also were found with other drug Classes in the following combinations: hydro-opiates, #5; diazepam, #9; methadone, #17; diazepam/hydro-opiates, #20; α-HO-alprazolam, #21; and cannabinoids, #25.
From a broader perspective, the unusually high prevalence of hydrocodone in comparison to oxycodone, methadone, and morphine as recorded in this study was surprising and deserves comment. But first, the terms "opiate" and "opioid" as used in this discussion need clarification. The term "opiate" denotes those analgesic drugs bearing a close structural relationship to morphine, whereas "opioid" is used in a broader sense to encompass all drugs that produce opiate-like analgesia. An analysis of "opioids" detected in this study provided a broader view of the types of pain medications used by this patient population (Table VII) . The relative frequency of opioid detection was as follows: hydrocodone > hydromorphone > dihydrocodeine > oxycodone > oxymorphone > morphine ≈ methadone > fentanyl > propoxyphene > codeine > meperidine. This pattern differs considerably from prescribing patterns and urine detection rates reported in other studies of chronic pain patients. Oxycodone has been reported as being the most widely prescribed opioid (9,10) and most often detected drug in urine specimens of chronic pain patients (9) . The second most frequently prescribed opioid in these studies was either methadone or morphine. In those studies, hydrocodone ranked #5 with a prescription rate of 7.7% (N = 470) in one study (9) and #3 with a prescription rate of 14% (N = 209) in the second study (10) .
A second aspect of opioid use relates to the issue of how often multiple opioid-type drugs are co-administered by pain patients. In this study, single use of an opioid (fentanyl, meperidine, methadone, hydro-opioid, oxy-opioid, and propoxyphene) accounted for 86.2% of all positive opioid results (N = 10,110). Multiple opioid uses occurred as follows: two opioids, 12.5%; three opioids, 1.2%; and four opioids, 0.1%. Use of two opioids can arise when patients are placed on long-acting opioid medications to control their persistent pain and shorter-acting medications to control breakthrough pain. Medications for breakthrough pain are typically an immediate release preparation of conventional, hydrophilic, shorter-acting opioids (e.g., morphine, hydromorphone, hydrocodone, and oxycodone). As noted, a small percentage of patients in this study (1.3%, N = 132) had used three or four opioids. It was noted that 16 of these patients also were positive for cannabis and an additional 6 were positive for cocaine metabolite. Undoubtedly, some of these patients were suffering from the disease of addiction.
Propoxyphene
A total of 385 (3.5%) urine specimens were positive for propoxyphene and/or norpropoxyphene in the propoxyphene Class. Norpropoxyphene detection was reported in higher frequency at 90.1% than propoxyphene at 49.6%. Mean concentrations (Table IV) were higher for the metabolite compared to parent drug.
Within-Class pattern analysis of the propoxyphene analytes indicated that norpropoxyphene was identified as the single analyte in 50.4% of specimens positive for this class (Table V) . Norpropoxyphene in combination with propoxyphene was identified in 39.7% of the results and 9.9% contained only propoxyphene.
Between-drug Group analysis revealed that propoxyphene analytes appeared two times among the 25 most frequently reported single/multiple drug Group combinations (Table VI) . Specimens positive only for propoxyphene were ranked #13 in frequency. Propoxyphene in combination with hydro-opiates was ranked #18.
Evidence of illicit drug use in pain patients
A total of 1195 (10.9%) of all specimens in this study were confirmed positive for various combinations of THCCOOH (cannabis), benzoylecgonine (cocaine), MDMA ("Ecstasy"), and MDA ("Eve"). Numerous licit drugs were also recorded for many of these specimens. Of the 1195 specimens, THCCOOH was present as the sole illicit drug in 73.8%; benzoylecgonine was present in 19.1%; and 6.8% contained THCCOOH in combination with benzoylecgonine. In addition, two (0.2%) specimens were positive for THCCOOH, MDMA, and MDA; one (0.1%) was positive for THCCOOH, benzoylecgonine, MDMA, and MDA; and one (0.1%) was positive for THCCOOH and MDA. It seems likely that those specimens containing THC-COOH and/or benzoylecgonine arose primarily from illicit drug use. Although tetrahydrocannabinol (THC) can be obtained as a prescription drug (Marinol ® ) in the United States for treatment of anorexia in AIDS patients and for nausea and vomiting associated with cancer chemotherapy, it is unlikely to be widely prescribed to chronic non-cancer pain patients. Cocaine is used very infrequently in surgical procedures, and MDMA and MDA are only available in the illicit drug market. It is known that a significant percent of chronic pain patients suffer from drug and alcohol addiction. Fishbain et al. (6) estimated the prevalence at 3.2% to 18.9%. Rates of illicit drug use in chronic pain patients are difficult to ascertain and frequently are based on "on-site" screening data, thereby limiting interpretation. Katz et al. (23) utilized immunoassay screening and GC-MS confirmation procedures to ascertain the role of urine toxicology in monitoring non-cancer pain patients on long-term opioid therapy. Of 122 patients monitored, 26 (21.3%) had toxicology results demonstrating use of an illicit drug. Twenty (16.4%) specimens were positive for cannabis, and six (4.9%) were positive for cocaine. An additional 11 (9.0%) specimens were positive for licit non-prescribed drugs. In another study, Michna et al. (9) utilized urine testing with GC-MS confirmation to evaluate 470 chronic pain patients. Cannabis use was detected at a prevalence of 14.5% and cocaine use was 6.8%. In a Canadian study of pain patients (N = 209), 10% of patients were current cannabis users (27) . A somewhat lower frequency of illicit drug use of 10.9% in pain patients was recorded in the current study.
Conclusions
This study presents a comprehensive evaluation of urine toxicology data arising from testing chronic pain patients in a clinical setting. A total of 10,922 urine specimens from pain patients in 31 pain clinics in the United States in 2006 were analyzed by immunoassay with GC-MS confirmation for 36 drug and/or metabolites. Quantitative results (N = 27,197) were recorded for 32 analytes. Collation of the results into 11 general drug Classes and 19 specific drug Groups allowed comparison within and between drug types.
Significant findings were as follows:
The overall frequency of drug positives was as follows: opiates >> benzodiazepines > methadone > cannabinoids > carisoprodol > fentanyl > propoxyphene > barbiturates > cocaine > amphetamines > meperidine.
Illicit drug use: the overall prevalence of illicit drug use (cannabis, cocaine, ecstasy-type drugs) was 10.9%; the prevalence of THCCOOH was approximately threefold higher than cocaine; ecstasy-type drugs were detected in four specimens.
Amphetamines: amphetamines were detected in 160 specimens (1.5% of total specimens); amphetamine was the predominant drug within the amphetamines Class representing 51.3% of positives; methamphetamine accounted for 25.6%, most of which were found in combination with amphetamine; phentermine positives accounted for 21.9%; ecstasy-type drugs (MDMA/MDA) were identified in four specimens.
Barbiturates: barbiturates were detected in 308 specimens (2.8% of total specimens); butalbital was the predominant drug within the barbiturates Class representing 98.7% of pos-new area of toxicology testing requires methodology suitable for quantitation of a broad range of psychoactive drugs and metabolites at both low and ultra-high concentrations. Extremely high confirmation rates are needed as part of normal operations. This first study of chronic pain patients offers an array of licit and illicit drug testing information regarding drug frequency, concentrations, drug/metabolite patterns, and a plethora of drug combinations encountered when testing this population.
